The Journal of Organic Chemistry
Note
5.23 (s, 2H), 4.21 (d, J = 6.4 Hz, 0.36H), 3.99 (d, J = 5.7 Hz, 1.64H),
3.96−3.90 (m, 2H), 1.95 (br s, 1H); 13C NMR (151 MHz, CDCl3)
major isomer δ 158.2, 158.1, 151.6, 138.5, 138.3, 137.5, 131.1, 129.4,
128.6, 127.9, 127.5, 123.5, 119.8, 117.4, 107.3, 103.7, 103.5, 70.1, 63.3,
32.5; minor isomer δ 151.5, 138.5, 138.3, 137.5, 130.3, 128.9, 127.5,
123.5, 117.3, 107.5, 103.8, 103.3, 58.5, 28.1; HRMS (ESI) m/z calcd
for C23H21N3NaO2 [M + Na]+ 394.1526, found 394.1524.
1H), 7.09−7.04 (m, 1H), 6.53 (s, 1H), 5.85−5.60 (m, 2H), 4.23 (d, J
= 5.2 Hz, 0.37H), 4.02 (d, J = 5.1 Hz, 1.63H), 3.96−3.89 (m, 2H),
1.79 (br s, 1H); 13C NMR (151 MHz, CDCl3) major isomer δ 158.2,
157.7, 140.5, 137.1, 131.4, 129.5, 128.6, 124.6, 123.5, 117.6, 113.6,
112.8, 105.9, 63.2, 32.4; minor isomer δ 140.6, 137.2, 130.5, 129.5,
128.3, 124.6, 123.5, 117.6, 112.9, 105.8, 58.4, 28.0; MS (ESI) m/z
(relative intensity) 366.2 (100) [M + Na]+. The NMR data agree with
those in a literature report.31
4-(5-Bromo-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (3n).
Product 3n was obtained as a pale yellow oil (183.8 mg, 89%, E/Z
= 4.0:1 by 1H NMR): 1H NMR (600 MHz, CDCl3) δ 8.69 (d, J = 4.7
Hz, 2H), 8.27−8.13 (m, 1H), 7.61−7.56 (m, 1H), 7.29−7.24 (m, 1H),
7.09−7.05 (m, 1H), 6.35 (s, 1H), 5.80−5.55 (m, 2H), 4.18 (d, J = 4.7
Hz, 0.4H), 3.97 (d, J = 5.4 Hz, 1.6H), 3.91−3.80 (m, 2H), 2.26 (br s,
1H); 13C NMR (151 MHz, CDCl3) major isomer δ 158.2, 157.7,
141.2, 135.7, 131.4, 130.9, 128.7, 125.3, 122.3, 117.5, 115.5, 115.0,
105.6, 63.1, 32.5; minor isomer δ 130.6, 128.4, 125.4, 117.5, 115.7,
115.0, 105.5, 58.4, 28.2; HRMS (ESI) m/z calcd for C16H14N3BrNaO
[M + Na]+ 366.0212, found 366.0220.
2-(4-Hydroxybut-2-en-1-yl)-1-(pyrimidin-2-yl)-1H-indole-5-car-
bonitrile (3h). Product 3h was obtained as a colorless sticky oil (48.8
1
1
mg, 28%, E/Z = 2.6:1 by H NMR): H NMR (600 MHz, CDCl3) δ
8.85 (d, J = 4.8, 2H), 8.29−8.23 (m, 1H), 7.85−7.83 (m, 1H), 7.46−
7.43 (m, 1H), 7.31−7.25 (m, 1H), 6.53 (s, 1H), 5.86−5.63 (m, 2H),
4.26 (d, J = 6.3 Hz, 0.55H), 4.06 (d, J = 5.8 Hz, 1.45H), 3.99−3.92 (m,
2H), 1.61 (br s, 1H); 13C NMR (151 MHz, CDCl3) major isomer δ
158.4, 157.4, 142.3, 138.7, 131.7, 128.9, 128.3, 125.7, 124.7, 120.4,
118.2, 114.5, 105.9, 104.7, 63.2, 32.3; minor isomer δ 138.7, 130.8,
128.0, 125.8, 120.3, 118.1, 114.6, 105.8, 104.8, 58.5, 28.0; HRMS
(ESI) m/z calcd for C17H14N4NaO [M + Na]+ 313.1060, found
313.1062.
4-(5-Fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (3i).
4-(6-Bromo-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (3o).
Product 3i was obtained as a white solid (161.6 mg, 90%, E/Z =
Product 3o was obtained as a colorless oil (179.6 mg, 87%, E/Z =
1
1
1
1
2.7:1 by H NMR): mp 94−96 °C; H NMR (600 MHz, CDCl3) δ
8.74 (d, J = 4.8 Hz, 2H), 8.27−8.15 (m, 1H), 7.16 (d, J = 9.0 Hz, 1H),
7.12 (t, J = 4.8 Hz, 1H), 6.94 (t, J = 9.1 Hz, 1H), 6.42 (s, 1H), 5.86−
5.61(m, 2H), 4.23 (d, J = 5.3 Hz, 0.54H), 4.02 (d, J = 5.8 Hz, 1.46H),
3.97−3.90 (m, 2H), 1.83 (br s, 1H); 13C NMR (151 MHz, CDCl3)
major isomer δ 158.7 (d, JC−F = 269.2 Hz), 158.1, 158.0, 141.4, 133.4,
131.2, 129.8 (d, JC−F = 10.0 Hz), 129.0, 117.2, 114.8 (d, JC−F = 9.1
Hz), 110.3 (d, JC−F = 25.0 Hz), 106.2 (d, JC−F = 4.0 Hz), 105.0 (d, JC−F
= 23.5 Hz), 63.2, 32.6; minor isomer δ 130.3, 128.6, 117.2, 115.0 (d,
JC−F = 9.1 Hz), 110.3 (d, JC−F = 24.9 Hz), 106.0 (d, JC−F = 3.9 Hz),
58.4, 28.2; HRMS (ESI) m/z calcd for C16H14N3FNaO [M + Na]+
306.1013, found 306.1021.
3.5:1 by H NMR): H NMR (600 MHz, CDCl3) δ 8.77 (d, J = 4.8
Hz, 2H), 8.48−8.44 (m, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.30−7.27 (m,
1H), 7.15 (t, J = 4.8 Hz, 1H), 6.43 (s, 1H), 5.86−5.61 (m, 2H), 4.24
(d, J = 4.6 Hz, 0.44H), 4.03 (d, J = 5.5 Hz, 1.56H), 3.96−3.89 (m,
2H), 1.51 (br s, 1H); 13C NMR (151 MHz, CDCl3) major isomer δ
158.2, 157.8, 140.4, 137.6, 131.2, 129.1, 128.0, 125.0, 120.8, 117.4,
116.9, 116.3, 106.2, 63.3, 32.5; minor isomer 137.6, 130.4, 128.7,
125.0, 117.4, 117.1, 116.3, 106.1, 58.5, 28.2; HRMS (ESI) m/z calcd
for C16H14BrN3NaO [M + Na]+ 366.0212, found 366.0206.
2-Phenyl-4-(1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (3p).
Product 3p was obtained as a yellow oil (200.5 mg, 98%, E/Z =
1
1
4.0:1 by H NMR): H NMR (600 MHz, CDCl3) δ 8.74 (d, J = 4.8
Hz, 0.4H), 8.66 (d, J = 4.8 Hz, 1.6H), 8.28 (d, J = 8.3 Hz, 0.2H), 8.19
(d, J = 8.4 Hz, 1.8H), 7.52 (d, J = 7.3 Hz, 1H), 7.39−7.15 (m, 7H),
7.09 (t, J = 4.8 Hz, 0.2H), 6.99 (t, J = 4.8 Hz, 0.8H), 6.47 (d, J = 5.6
Hz, 1H), 5.89−5.58 (m, 2H), 5.06 (d, J = 6.8 Hz, 1H), 4.19−4.14 (m,
0.2H), 4.0−3.91 (m, 1.8H), 2.11 (s, 0.2H), 1.98 (s, 0.8H); 13C NMR
(151 MHz, CDCl3) major isomer δ 158.0, 157.9, 142.9, 139.3, 137.0,
134.2, 129.1, 129.0, 128.4, 127.4, 126.1, 122.7, 121.8, 119.8, 117.1,
113.7, 106.6, 74.8, 32.4; minor isomer δ 158.1, 143.3, 139.4, 137.1,
133.5, 129.1, 128.5, 127.5, 126.0, 122.8, 121.9, 119.9, 113.9, 69.6, 28.4;
HRMS (ESI) m/z calcd for C22H19N3NaO [M + Na]+ 364.1420,
found 364.1429.
4-(5-Chloro-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (3j).
Product 3j was obtained as a colorless oil (158.3 mg, 88%, E/Z =
1
1
3.3:1 by H NMR): H NMR (600 MHz, CDCl3) δ 8.78 (d, J = 4.8
Hz, 2H), 8.27−8.13 (m, 1H), 7.47 (d, J = 1.7 Hz, 1H), 7.20−7.11 (m,
2H), 6.41 (s, 1H), 5.89−5.62 (m, 2H), 4.26 (d, J = 4.6 Hz, 0.47H),
4.05 (d, J = 5.6 Hz, 1.53H), 3.99−3.90 (m, 2H), 1.99 (br s, 1H); 13C
NMR (151 MHz, CDCl3) major isomer δ 158.2, 157.9, 141.2, 135.4,
131.3, 130.3, 129.1, 127.3, 122.7, 119.2, 117.4, 115.0, 105.8, 63.3, 32.6;
minor isomer δ 130.4, 128.8, 127.3, 122.8, 119.2, 117.4, 115.2, 105.7,
58.6, 28.2; HRMS (ESI) m/z calcd for C16H14N3ClNaO [M + Na]+
322.0718, found 322.0728.
4-(4-Chloro-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (3k).
2-(4-Fluorophenyl)-4-(1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-
Product 3k was obtained as a colorless oil (156.5 mg, 87%, E/Z =
1-ol (3q). Product 3q was obtained as a yellow oil (202.9 mg, 94%, E/
1
1
1
1
4.0:1 by H NMR): H NMR (600 MHz, CDCl3) δ 8.77 (d, J = 4.8
Hz, 2H), 8.15−8.09 (m, 1H), 7.19−7.11 (m, 3H), 6.59 (s, 1H), 5.88−
5.61 (m, 2H), 4.25 (d, J = 5.4 Hz, 0.4H), 4.03 (d, J = 6.8 Hz, 1.6H),
3.98−3.90 (m, 2H), 1.70 (br s, 1H); 13C NMR (151 MHz, CDCl3)
major isomer δ 158.2, 157.8, 140.5, 137.6, 131.4, 128.8, 127.7, 125.0,
123.2, 121.5, 117.6, 112.3, 104.3, 63.3, 32.4; minor isomer δ 140.5,
137.6, 130.5, 128.5, 123.3, 121.6, 117.6, 112.4, 104.2, 58.5, 28.1;
HRMS (ESI) m/z calcd for C16H14ClN3NaO [M + Na]+ 322.0718,
found 322.0715.
Z = 5.3:1 by H NMR): H NMR (600 MHz, CDCl3) δ 8.78 (d, J =
4.8 Hz, 0.32H), 8.71 (d, J = 4.8 Hz, 1.68H), 8.30 (d, J = 8.3 Hz,
0.16H), 8.22 (d, J = 8.3 Hz, 0.84H), 7.56−7.51 (m, 1H), 7.38−7.12
(m, 5H), 7.08−6.94 (m, 3H), 6.47 (s, 1H), 5.91−5.56 (m, 2H), 5.07
(d, J = 6.8 Hz, 1H), 4.19−4.12 (m, 0.19H), 4.01−3.95 (m, 1.71H),
2.05 (s, 0.16H), 1.88 (s, 0.84H); 13C NMR (151 MHz, CDCl3) major
isomer δ 162.1 (d, JC−F = 245.5 Hz), 158.0, 158.0, 139.2, 138.7 (d, JC−F
= 2.9 Hz), 137.0, 134.0, 129.2, 129.0, 127.7 (d, JC−F = 8.1 Hz), 122.8,
121.9, 119.9, 117.1, 115.2 (d, JC−F = 21.3 Hz), 113.7, 74.2, 32.4; minor
isomer 162.1 (d, JC−F = 245.6 Hz), 158.2, 158.1, 139.3, 139.0 (d, JC−F
= 2.8 Hz), 137.1, 133.4, 129.1, 128.6, 127.6 (d, JC−F = 8.2 Hz), 122.9,
122.0, 119.9, 117.1, 115.3 (d, JC−F = 21.4 Hz), 114.0, 106.7, 69.0, 28.4;
HRMS (ESI) m/z calcd for C22H18FN3NaO [M + Na]+ 382.1326,
found 382.1333.
Experiment of H/D Exchange. Indole 1a (0.6 mmol), CD3OD
(1.2 mmol), [Cp*Co(MeCN)3][SbF6]2 (0.03 mmol, 5 mol %),
AgOAc (0.12 mmol, 20 mol %), and silica gel (600 mg, grinding
auxiliary) were transferred to a ball-milling vessel (stainless steel, 45
mL) loaded with 36 grinding balls (stainless steel, 4 mm). The milling
vessel was placed in the ball mill (800 rpm, 30 min). The crude
product was isolated by washing the vessel and the balls with EtOAc
(3× 20 mL). The mixture was concentrated in vacuum and purified by
flash chromatography (Hexane/EtOAc = 4:1 to 2:1). Recovery: 98%
of 1a and 1a-[D]n.
4-(6-Chloro-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (3l).
Product 3l was obtained as a colorless oil (163.6 mg, 91%, E/Z =
1
1
4.0:1 by H NMR): H NMR (600 MHz, CDCl3) δ 8.79 (d, J = 4.8
Hz, 2H), 8.34−8.29 (m, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.19−7.14 (m,
1H), 6.44 (s, 1H), 5.88−5.63 (m, 2H), 4.26 (d, J = 5.2 Hz, 0.4H) 4.05
(d, J = 5.8 Hz, 1.6H), 3.99−3.90 (m, 2H), 1.59 (br s, 1H); 13C NMR
(151 MHz, CDCl3) major isomer δ 158.2, 157.8, 140.5, 137.3, 131.2,
129.1, 128.5, 127.6, 122.3, 120.4, 117.4, 114.1, 106.2, 63.3, 32.5; minor
isomer δ 157.8, 137.3, 130.3, 128.8, 128.6, 122.4, 117.4, 114.2, 106.0,
58.5, 28.2; HRMS (ESI) m/z calcd for C16H14ClN3NaO [M + Na]+
322.0718, found 322.0706.
4-(4-Bromo-1-(pyrimidin-2-yl)-1H-indol-2-yl)but-2-en-1-ol (3m).
Product 3m was obtained as a colorless oil (175.1 mg, 85%, E/Z =
1
1
4.4:1 by H NMR): H NMR (600 MHz, CDCl3) δ 8.76 (d, J = 4.8
Hz, 2H), 8.18−8.12 (m, 1H), 7.34 (d, J = 7.6 Hz, 1H), 7.17−7.13 (m,
F
J. Org. Chem. XXXX, XXX, XXX−XXX